Payment overview · 2025
General Payments
$1,606.76
67 reported records · 22 companies
Healthcare provider profile · identity verified
Prabhat Kumar Sinha, MD
Allopathic & Osteopathic Physicians|Internal Medicine · TOMS RIVER, NJ · NPI 1013988286
Verified facts
What the public records show
CMS Open Payments records show Prabhat Kumar Sinha, MD received $1,606.76 in general payments during 2025 across 67 reported records.
AstraZeneca Pharmaceuticals LP accounted for 22.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 521 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 521 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $366.51 | 22.8% | 9 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $203.82 | 12.7% | 8 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $203.08 | 12.6% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $175.10 | 10.9% | 12 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $127.15 | 7.9% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $63.45 | 4.0% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $58.39 | 3.6% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $49.68 | 3.1% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $44.92 | 2.8% | 2 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $39.26 | 2.4% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.56 | 2.1% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $32.93 | 2.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $29.88 | 1.9% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.13 | 1.7% | 2 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.73 | 1.4% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $21.75 | 1.4% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $19.79 | 1.2% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $19.22 | 1.2% | 1 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $18.34 | 1.1% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $18.20 | 1.1% | 1 | 2025 |
| InSightec,Inc | Unresolved — no canonical attribution shown | $15.96 | 1.0% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $15.91 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,606.76 | 67 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $284.86 | 4 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $203.82 | 8 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $203.08 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $175.10 | 12 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $175.10 | 12 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $127.15 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $121.84 | 7 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $78.84 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $61.46 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $44.92 | 2 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $39.26 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $32.93 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $31.10 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $30.51 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $27.13 | 2 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $22.73 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $21.75 | 1 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $19.79 | 1 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $19.22 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.58 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.58 | 1 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $18.34 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $18.20 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $17.59 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $16.96 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.56 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $16.37 | 1 | 2025 |
Source payment records
|
|||||
| Exablate Normalized: exablate |
Device | InSightec,Inc | $15.96 | 1 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | Regeneron Healthcare Solutions, Inc. | $15.91 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 521 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 80 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 86 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 35 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
33 | 14 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
80 | 21 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
86 | 26 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
521 | 84 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
35 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
86 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
68 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
64 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
521 | 84 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 957 | 250 |
| Levothyroxine Sodium | Levothyroxine Sodium | 752 | 192 |
| Amlodipine Besylate | Amlodipine Besylate | 743 | 187 |
| Pantoprazole Sodium | Pantoprazole Sodium | 574 | 173 |
| Metformin Hcl | Metformin Hcl | 550 | 150 |
| Eliquis | Apixaban | 521 | 84 |
| Furosemide | Furosemide | 513 | 142 |
| Gabapentin | Gabapentin | 488 | 94 |
| Losartan Potassium | Losartan Potassium | 457 | 137 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 435 | 151 |
| Metoprolol Succinate | Metoprolol Succinate | 347 | 122 |
| Sertraline Hcl | Sertraline Hcl | 343 | 57 |
| Tamsulosin Hcl | Tamsulosin Hcl | 325 | 96 |
| Trazodone Hcl | Trazodone Hcl | 302 | 64 |
| Lisinopril | Lisinopril | 300 | 81 |
| Metoprolol Tartrate | Metoprolol Tartrate | 271 | 80 |
| Escitalopram Oxalate | Escitalopram Oxalate | 263 | 58 |
| Potassium Chloride | Potassium Chloride | 242 | 57 |
| Alprazolam | Alprazolam | 235 | 76 |
| Duloxetine Hcl | Duloxetine Hcl | 231 | 45 |
| Divalproex Sodium | Divalproex Sodium | 221 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 218 | 72 |
| Simvastatin | Simvastatin | 211 | 55 |
| Famotidine | Famotidine | 210 | 42 |
| Montelukast Sodium | Montelukast Sodium | 195 | 63 |
| Mirtazapine | Mirtazapine | 193 | 41 |
| Pravastatin Sodium | Pravastatin Sodium | 179 | 64 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 177 | 86 |
| Carvedilol | Carvedilol | 172 | 43 |
| Buspirone Hcl | Buspirone Hcl | 148 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 148 | 32 |
| Donepezil Hcl | Donepezil Hcl | 145 | 38 |
| Levetiracetam | Levetiracetam | 140 | 27 |
| Quetiapine Fumarate | Quetiapine Fumarate | 139 | 40 |
| Allopurinol | Allopurinol | 134 | 34 |
| Memantine Hcl | Memantine Hcl | 133 | 29 |
| Januvia | Sitagliptin Phosphate | 127 | 22 |
| Prednisone | Prednisone | 127 | 74 |
| Omeprazole | Omeprazole | 125 | 47 |
| Ondansetron Hcl | Ondansetron Hcl | 125 | 30 |
| Clonazepam | Clonazepam | 119 | 33 |
| Ozempic | Semaglutide | 116 | 33 |
| Glipizide Er | Glipizide | 113 | 37 |
| Clonidine Hcl | Clonidine Hcl | 112 | 19 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 112 | suppressed |
| Nifedipine Er | Nifedipine | 110 | 38 |
| Fluticasone Propionate | Fluticasone Propionate | 108 | 57 |
| Hydrochlorothiazide | Hydrochlorothiazide | 100 | 43 |
| Spironolactone | Spironolactone | 95 | 32 |
| Olanzapine | Olanzapine | 94 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 91 | 17 |
| Sucralfate | Sucralfate | 91 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 90 | 23 |
| Lorazepam | Lorazepam | 90 | 29 |
| Divalproex Sodium Er | Divalproex Sodium | 86 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 86 | 14 |
| Jardiance | Empagliflozin | 86 | 26 |
| Tramadol Hcl | Tramadol Hcl | 85 | 34 |
| Baclofen | Baclofen | 83 | 19 |
| Xarelto | Rivaroxaban | 81 | 24 |
| Farxiga | Dapagliflozin Propanediol | 80 | 21 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 79 | 21 |
| Doxazosin Mesylate | Doxazosin Mesylate | 78 | 29 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 77 | 66 |
| Insulin Lispro | Insulin Lispro | 76 | 14 |
| Cefuroxime | Cefuroxime Axetil | 75 | 63 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 75 | 34 |
| Enalapril Maleate | Enalapril Maleate | 75 | 22 |
| Risperidone | Risperidone | 74 | 13 |
| Entresto | Sacubitril/Valsartan | 72 | 14 |
| Eszopiclone | Eszopiclone | 71 | 21 |
| Finasteride | Finasteride | 69 | 15 |
| Azithromycin | Azithromycin | 68 | 48 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 68 | 13 |
| Mounjaro | Tirzepatide | 68 | 16 |
| Midodrine Hcl | Midodrine Hcl | 66 | 33 |
| Oxcarbazepine | Oxcarbazepine | 65 | suppressed |
| Pregabalin | Pregabalin | 65 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 64 | suppressed |
| Trulicity | Dulaglutide | 64 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 64 | 20 |
| Lactulose | Lactulose | 63 | 18 |
| Aripiprazole | Aripiprazole | 61 | 11 |
| Celecoxib | Celecoxib | 61 | 28 |
| Fluoxetine Hcl | Fluoxetine Hcl | 61 | 15 |
| Valsartan | Valsartan | 60 | 16 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 56 | suppressed |
| Haloperidol | Haloperidol | 55 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 54 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 53 | 21 |
| Amoxicillin | Amoxicillin | 52 | 35 |
| Propranolol Hcl | Propranolol Hcl | 52 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 51 | 44 |
| Doxycycline Hyclate | Doxycycline Hyclate | 51 | 37 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 50 | suppressed |
| Ezetimibe | Ezetimibe | 50 | 17 |
| Glipizide | Glipizide | 49 | 20 |
| Cephalexin | Cephalexin | 48 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 47 | 11 |
| Ibuprofen | Ibuprofen | 46 | 16 |
| Bupropion Xl | Bupropion Hcl | 45 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 45 | 17 |
| Topiramate | Topiramate | 45 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 44 | 33 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 43 | 32 |
| Phenytek | Phenytoin Sodium Extended | 43 | suppressed |
| Lamotrigine | Lamotrigine | 42 | 11 |
| Bumetanide | Bumetanide | 41 | 14 |
| Carbamazepine | Carbamazepine | 41 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 41 | 15 |
| Nystatin | Nystatin | 41 | 21 |
| Austedo | Deutetrabenazine | 40 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 40 | suppressed |
| Latanoprost | Latanoprost | 40 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 40 | 13 |
| Glimepiride | Glimepiride | 39 | suppressed |
| Ramipril | Ramipril | 39 | 14 |
| Humalog Kwikpen U-100 | Insulin Lispro | 38 | 12 |
| Labetalol Hcl | Labetalol Hcl | 38 | suppressed |
| Primidone | Primidone | 38 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 37 | suppressed |
| Digoxin | Digoxin | 37 | 13 |
| Meloxicam | Meloxicam | 37 | 15 |
| Nyamyc | Nystatin | 37 | suppressed |
| Temazepam | Temazepam | 37 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 36 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | 13 |
| Chlorthalidone | Chlorthalidone | 34 | 11 |
| Diltiazem Hcl | Diltiazem Hcl | 34 | 11 |
| Levofloxacin | Levofloxacin | 33 | 24 |
| Linzess | Linaclotide | 33 | suppressed |
| Synthroid | Levothyroxine Sodium | 33 | 14 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 32 | 15 |
| Diltiazem 24hr Er | Diltiazem Hcl | 32 | suppressed |
| Atenolol | Atenolol | 31 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 31 | 12 |
| Methylprednisolone | Methylprednisolone | 31 | 28 |
| Timolol Maleate | Timolol Maleate | 31 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 30 | 11 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 30 | 16 |
| Budesonide | Budesonide | 29 | suppressed |
| Enulose | Lactulose | 29 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 29 | 12 |
| Meclizine Hcl | Meclizine Hcl | 29 | suppressed |
| Torsemide | Torsemide | 29 | suppressed |
| Nystop | Nystatin | 28 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 17 |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | 12 |
| Sulfasalazine | Sulfasalazine | 27 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 27 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 26 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 26 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 26 | suppressed |
| Olanzapine Odt | Olanzapine | 26 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 26 | 15 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | 12 |
| Lansoprazole | Lansoprazole | 25 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 25 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | 11 |
| Sevelamer Carbonate | Sevelamer Carbonate | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Diazepam | Diazepam | 24 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 24 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 21 |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 23 | suppressed |
| Paliperidone Er | Paliperidone | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 22 | suppressed |
| Hydrocortisone | Hydrocortisone | 22 | 15 |
| Lidocaine | Lidocaine | 22 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Fluconazole | Fluconazole | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 21 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Humalog | Insulin Lispro | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Repaglinide | Repaglinide | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Scopolamine | Scopolamine | 19 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 18 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 18 | suppressed |
| Amlodipine-Valsartan-Hctz | Amlodipine/Valsartan/Hcthiazid | 18 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | 12 |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 18 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 18 | 12 |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 18 | suppressed |
| Risperidone Odt | Risperidone | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 16 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 16 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 15 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 15 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 15 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 15 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | 11 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 14 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 14 | suppressed |
| Clotrimazole | Clotrimazole | 14 | suppressed |
| Leflunomide | Leflunomide | 14 | suppressed |
| Letrozole | Letrozole | 14 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Prolia | Denosumab | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Repatha Syringe | Evolocumab | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Cyclosporine | Cyclosporine | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 12 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Pulmicort Flexhaler | Budesonide | 12 | suppressed |
| Alogliptin | Alogliptin Benzoate | 11 | suppressed |
| Aristada | Aripiprazole Lauroxil | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Dexamethasone | Dexamethasone | 11 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Restasis | Cyclosporine | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 11 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,606.76 · 67 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, Briviact, CAPLYTA, COBENFY, DUPIXENT, Dexcom G6 Transmitter, ELIQUIS, Exablate, FARXIGA, GEMTESA, General - Pain Management, JARDIANCE, KISUNLA, Kerendia, Korlym, NURTEC ODT, OFEV, OTEZLA, PURIFIED CORTROPHIN GEL, QULIPTA, REPATHA, REXULTI, Senza, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, ZAVZPRET | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error